13F Holdings
中文EN

BMY BRISTOL MYERS SQUIBB CO

Pharmaceutical Preparations · NYSE · SEC CIK 14272 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.2%
TTM net income YoY53.1%
TTM EPS YoY51.9%
Revenue 3-yr CAGR3.6%
Net income 3-yr CAGR3.7%

Margins

Gross margin69.2%
Operating margin—
Net margin18.5%
FCF margin18.6%
EBITDA margin—

Returns

ROE44.1%
ROA10.0%
ROIC (approx.)—
Asset turnover0.54x

Leverage & solvency

Liabilities / assets73.6%
Debt / equity1.83x
Current ratio1.59x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.15x
Accruals ratio-1.5%
Payout ratio55.4%
Capex / revenue2.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$48.19B$48.30B$45.01B$46.16B$46.38B
Cost of revenue$13.94B$13.97B$10.69B$10.14B$9.94B
Gross profit$34.26B$34.33B$34.31B$36.02B$36.45B
R&D expense$9.95B$11.16B$9.30B$9.51B$10.20B
SG&A expense$7.27B$8.41B$7.77B$7.81B$7.69B
Interest expense$1.89B$1.95B$1.17B$1.23B$1.33B
Pretax income$9.33B-$8.38B$8.44B$7.71B$8.10B
Income tax$2.27B$554.00M$400.00M$1.37B$1.08B
Net income$7.05B-$8.95B$8.03B$6.33B$6.99B
EPS (basic)3.47-4.413.882.973.15
EPS (diluted)3.46-4.413.862.953.12
Dividends declared per share2.492.422.312.192.01
Weighted avg. shares (diluted)2.04B2.03B2.08B2.15B2.25B
Balance sheet
Cash & equivalents$10.21B$10.35B$11.52B$9.32B$14.32B
Short-term investments$464.00M$513.00M$816.00M$130.00M$2.99B
Receivables$9.59B$9.01B$8.88B$8.15B$7.98B
Inventory$2.69B$2.56B$2.66B$2.34B$2.10B
Current assets$29.39B$29.78B$31.77B$27.27B$33.26B
PP&E, net$7.54B$7.14B$6.65B$6.25B$6.05B
Goodwill$21.75B$21.72B$21.17B$21.15B$20.50B
Intangibles$19.10B$23.31B$27.07B$35.86B$42.53B
Total assets$90.04B$92.60B$95.16B$96.82B$109.31B
Current liabilities$23.42B$23.77B$22.26B$21.89B$21.87B
Short-term debt$2.26B$2.05B$3.12B$4.26B$4.95B
Long-term debt$42.85B$47.60B$36.65B$35.06B$39.60B
Total debt$45.11B$49.65B$39.77B$39.32B$44.55B
Total liabilities$71.53B$76.22B$65.67B$65.70B$73.31B
Shareholders' equity$18.47B$16.34B$29.43B$31.06B$35.95B
Net debt$34.90B$39.30B$28.25B$30.00B$30.24B
Cash flow statement
Operating cash flow$14.16B$15.19B$13.86B$13.07B$16.21B
Capital expenditure$1.31B$1.25B$1.21B$1.12B$973.00M
Free cash flow$12.85B$13.94B$12.65B$11.95B$15.23B
Investing cash flow-$4.13B-$21.35B-$2.29B-$1.06B-$538.00M
Financing cash flow-$10.35B$5.13B-$9.42B-$16.96B-$16.22B
Depreciation & amortization$4.01B$9.60B$9.76B$10.28B$10.69B
Stock-based compensation$553.00M$507.00M$518.00M$457.00M$583.00M
Dividends paid$5.04B$4.86B$4.74B$4.63B$4.40B
Share buybacks$0$0$5.16B$8.00B$6.29B

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.